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Abstract Exogenous and endogenous environmental
exposures and particularly infections may participate in the
breakage of tolerance and the induction of autoimmunity in
rheumatic diseases. Response to infections apparently
occurs years before clinical manifestations and features of
autoimmunity, such as autoantibodies, are detected years
before clinical manifestations in autoimmune rheumatic
diseases. In this review, we summarize the current evi-
dence for a potential causal link between infectious agents
and rheumatoid arthritis, systemic lupus erythematosus,
systemic sclerosis, Sjogren’s syndrome and ANCA-asso-
ciated vasculitis.
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Abbreviations
ab Antibody
ACPA Anti-citrullinated peptide antibody
CEP-1 Citrullinated a-enolase peptide-1
CIA Collagen-induced arthritis
EBV Epstein-Barr virus
EBNA-1 EBV nuclear antigen-1
ELS Ectopic lymphoid follicle-like structures
GVHD Graft-versus-host disease
hCMV Human cytomegalovirus
HCV Hepatitis C virus
HTLV Human T cell leukemia virus
IFN Interferon
IL Interleukin
LAMP Lysosomal membrane protein-2
mCMV Murine cytomegalovirus







TNF Tumor necrosis factor
Introduction
Infectious agents have long been suspected as initiating
agents (etiology) of rheumatic diseases. In the 19th cen-
tury, the belief that rheumatoid arthritis (RA) was caused
by mycobacteria led to treatment of rheumatoid arthritis
with gold salts used for the treatment of infectious diseases.
Epidemiological and family studies have shown that
environmental factors play a significant role in the devel-
opment of rheumatic diseases [1]. This is exemplified by
the low concordance rate of RA in monozygotic twins but
higher than that in dizygotic twins. Moreover, environ-
mental factors appear to work in a proper genetic back-
ground in various autoimmune rheumatic diseases [2].
Infectious agents are part of the environmental insults to
human beings. Infectious agents can cause autoimmunity
and autoimmune disease by various mechanisms. For
instance, an immune response to an infectious agent may
result in an autoimmune disease by molecular mimicry,
epitope spreading, bystander activation or pathogen per-
sistence [3, 4]. Another mechanism is through epigenetic
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changes [5, 6]. Bacterial agents but also commensal bac-
teria can cause epigenetic modification of host genes.
Epigenetic changes are DNA modification without change
in nucleotide sequence and post-translational histone
modification, all of which change chromatin configuration
and thus accessibility of genes to transcription machinery.
For example, intestinal commensal bacteria affect DNA
methylation of the Toll-like receptor 4 (TLR4) gene of the
host that recognizes the lipopolysaccharide of Gram (-)
bacteria [7]. Another means of epigenetic modification is
through microRNAs (miRNAs). miRNA is a small (20–30
nucleotide long) non-coding RNA that silences the target
gene by binding to its mRNA [8]. Besides endogenous
miRNAs, exogenous miRNAs can affect the expression of
human genes. For example, miR168a from consumed rice
can bind to human and mouse LDL receptor protein-1
mRNA and inhibit its translation [9].
In the following sections, we will present epidemio-
logical, clinical, immunological and experimental data that
link autoimmune rheumatic diseases with specific infec-
tious agents.
Rheumatoid arthritis
Rheumatoid arthritis is a chronic inflammatory polyarthritis
that affects most commonly the small joints of the hands and
feet and may affect extra-articular tissues and organs, most
importantly lungs and the cardiovascular system. In RA,
environmental factors appear to play a more significant role
than genetic factors. The concordance rate of RA around
14 % in monozygotic twins and 4 % in dizygotic twins
suggests a rather small influence of genetic factors on the
development of the disease [10–13]. Two environmental
factors are known as risk factors for RA, namely peri-
odontitis and cigarette smoking [10, 11, 14–16]. Among
genetic factors, HLA genes are the best studied genes in RA.
RA is associated with HLA-DRB1* alleles carrying a
common amino acid sequence at position 70–74 of the b
chain, which is refered to as shared epitope (SE, HLA-
DRB1*SE) [17, 18]. HLA-DRB1* alleles on antigen-pre-
senting cells present antigen to T cells. Therefore, and given
that interferon (IFN)-c (a Th1 product) and interleukin(IL)-
17 (a Th17 product) are elevated in RA, the association with
the HLA-DRB1*SE suggests that in RA, HLA-DRB1*SE
alleles present an arthritogenic peptide to T cells to initiate
an immune response that culminates in a cytokine cascade
with IFN-c, IL-17, tumor necrosis factor (TNF)-a and IL-6
[19, 20]. Alternatively, the HLA-DRB1*SE itself may be the
target of an immune response. For instance, the Epstein-Barr
virus (EBV) gp110 glycoprotein shares sequence homology
with HLA-DRB1*SE and an initial immune response to
EBV may later also involve human HLA-DRB1*SE by
molecular mimicry [21].
For many years, rheumatoid factor was the only evi-
dence for autoimmunity in RA. In recent years, citrulli-
nated proteins have been shown to be the targets of B cells
and T cells in RA. Citrulline derives from arginine residues
by post-translational modification of proteins through the
action of the enzyme peptidylarginine deiminase (PAD).
Anti-citrullinated peptide antibodies (ACPAs) appear up to
10 years before the onset of clinical arthritis in RA [22, 23]
and are a strong susceptibility factor for RA [23–25]. In
fact, ACPAs are detected in around 70 % of patients with
RA, and are correlated with the severity of the disease
[26, 27]. More interestingly, ACPAs are associated with
HLA-DRB1*SE [23–25]. The apparent explanation for
association is that T cells recognize citrullinated peptides
sitting on HLA-DRB1*SE on B cells and provide help to B
cells for the production of ACPAs. Indeed, HLA-
DRB1*SE alleles bind to citrullinated peptides in RA, as
citrulline but not arginine was eluted from HLA-
DRB1*04:01/04(SE) alleles [28]. In addition, CD4(?) T
cells from the peripheral blood of HLA-DRB1*04:01 (an
HLA-DRB1*SE allele) patients with RA, were found to
recognize citrullinated vimentin and citrullinated aggrecan
[28]. Furthermore, oligoclonal expansions of T cells were
detected in synovial biopsies from ACPA(?) RA patients
compared to ACPA(-) RA patients [29, 30]. It is worth
reminding that oligoclonal expansion of T cells indicates
an antigen-driven activation and proliferation of T cells.
As mentioned, two environmental factors, namely
periodontitis and cigarette smoking, are risk factors for RA
and may exert this susceptibility via protein citrullination
and ACPA production. Cigarette smoking is a strong
inducer of protein citrullination in a proper genetic back-
ground. Furthermore, cigarette smoking is a risk factor for
ACPA in RA patients carrying the HLA-DRB1*SE [31],
and this tobacco exposure-HLA-DRB1*SE interaction has
been confirmed in a number of studies [32–34]. Animal
models provide explanation for this association: tobacco
exposure induces PAD in transgenic mice carrying RA-
susceptible HLA-DR alleles [35], thus providing a means
for new antigens (autoantigens) to the immune system. P.
gingivalis, a microbe that is the major causative agent for
periodontitis, possesses PAD that can cause citrullination
of both bacterial and host proteins [36]. A citrullinated a-
enolase peptide-1 (CEP-1) was identified as a dominant B
cell epitope present in 36–60 % of RA patients [37]. It is
worth mentioning that CEP-1 is highly conserved in
prokaryotes and eukaryotes, and human CEP-1 shares
100 % homology of a 9 amino acid span with P. gingivalis
a-enolase [37]. Antibodies to human CEP-1 cross-reacted
with recombinant P. gingivalis a-enolase [37] and anti-
citrullinated bacterial a-enolase antibodies are detected in
ACPA(?) RA patients [38]. P. gingivalis can contribute to
RA through another mechanism. P. gingivalis DNA was
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detected in synovial fluid from RA patients more fre-
quently than in controls (15.7 vs 3.5 %) [39]. Furthermore,
P. gingivalis DNA can induce IL-1, IL-6 and TNFa pro-
duction in a monocytic cell line through TLR9 [40]. These
findings suggest that bacterial persistence in the joints may
also contribute to the synovial inflammation in RA.
Active EBV infection also appears to contribute to syn-
ovial membrane (SM) expansion and differentiation of
autoreactive B cells. For instance, in ectopic lymphoid,
follicle-like structures (ELS)-containing RA synovial
membrane, latent and lytic EBV infection were detected,
and a large proportion of plasma cells producing ACPAs
were infected with EBV. Furthermore, ELS-containing RA
SM transplanted into severe combined immunodeficiency
(SCID) mice produced ACPAs and anti-EBV antibodies
[41]. All the above data point to the notion that cross-re-
activity between bacteria and human citrullinated proteins
can break tolerance and induce arthritis.
The finding of an autoantigen does not prove its
pathogenicity, i.e., cause of tissue injury. Experimental
data support the notion that citrullinated peptides are
arthritogenic autoantigens in RA. Thus, both citrullination
of proteins and the HLA-DRB1* SE, are required for the
development of arthritis: citrullinated fibrinogen but not
unmodified fibrinogen could induce arthritis in transgenic
mice carrying DRB1*04:01 (an HLADRB1*SE allele). On
the other hand, citrullinated or unmodified fibrinogen could
not induce arthritis in wild-type (B6) mice [42]. ACPAs
against citrullinated vimentin induce osteoclastogenesis
and bone loss, cardinal features of joint involvement in RA
[43]. Also immune complexes containing citrullinated
fibrinogen stimulated macrophage TNFa production
through TLR4 and Fcc receptor [44]. In collagen-induced
arthritis, a PAD inhibitor reduced the severity of arthritis,
an effect that supports an arthritogenic role for citrullina-
tion and ACPA production in RA [45]. Furthermore, P.
gingivalis infection exacerbated collagen-induced arthritis
(CIA), and this exacerbation was dependent on the
expression of P. gingivalis PAD [46].
Citrullinated antigens are detected in neutrophil extra-
cellular traps (NETs), formed spontaneously or in stimu-
lated RA neutrophils [47, 48]. NETs are structures of
decondensed chromatin and granule antimicrobial lysoso-
mal proteins, such as proteinase-3, myeloperoxidase,
lactoferrin, elastase and others. NETs are extruded from
neutrophils while dying (NETosis) to kill bacteria [49].
ACPAs may be produced in lymphoid organs, as most
antibodies, or in local tissues. Higher expression of PAD2
was detected in bronchial mucosa and bronchoalveolar
lavage cells in healthy smokers compared to non-smokers
[50]. The inflamed synovial membrane of RA is a site for
ACPA production, since ACPA levels were higher in
synovial fluid compared with serum from the same patients
[24, 51]. Further supporting evidence comes from the
finding that the majority of synovial membrane IgG-ex-
pressing B cells are specific for citrullinated autoantigens
in ACPA(?) RA patients [52]. It has already been men-
tioned that ACPAs are produced in RA synovial membrane
as ELS-containing RA SM transplanted into SCID mice
produced ACPAs along with anti-EBV antibodies [41].
The gut microbiome may also affect the immune
response in a proper genetic background in RA. For
example, transgenic mice carrying the RA-susceptible
allele HLA-DRB1*04:01 have a differential Th17 cytokine
profile and do not exhibit the sex- and age-difference in gut
microbiome that transgenic mice carrying the RA-resistant
allele HLA-DRB1*04;02 exhibit [53].
Systemic sclerosis
Systemic sclerosis (SSc) is a chronic systemic disease
characterized by fibrosis of the skin and internal organs,
vasculopathy, and activation of the immune system. Vas-
culopathy comprises of vasospastic episodes (Raynaud’s
phenomenon, RP) and fibrointimal proliferation of small
vessels, whereas immune activation is evident by serum
autoantibodies detected in patients with SSc, and the
oligoclonal expansion of T cells in skin lesions [54]. The
best known autoantibodies in SSc are antinuclear anti-
bodies and anti-topoisomerase I antibodies (formerly
Scl70), which are associated with diffuse cutaneous dis-
ease, and anti-centromere antibodies, which are associated
with limited cutaneous disease. RP and autoantibodies
appear years before clinical manifestations of fibrosis, and
microvascular damage (as detected by nailfold capil-
laroscopy) and autoantibodies are independent predictors
for the progression of RP to SSc [55]. The pathogenesis of
SSc is incompletely understood [56]. In the avian sclero-
derma model, endothelial cell apoptosis was the earliest
change detected [57]. Environmental factors play a major
role in the development of the disease since the concor-
dance rate of SSc in monozygotic twins is low (4.7 %) and
equal to dizygotic twins [58]. Molecular mimicry has been
suggested as early pathogenetic mechanism for SSc and
several microbes have been implicated, including human
cytomegalovirus (hCMV), EBV, endogenous retroviruses
and H. pylori. The strongest data supporting a pathogenetic
role in SSc holds for hCMV and EBV. Early studies
reported increased serum levels of anti-hCMV antibodies
in SSc patients [59]. In addition, SSc patients have anti-
bodies against an epitope of the hCMV late protein UL94,
that shares homology with the novel antigen-2 (NAG-2),
present on endothelial cells. Anti-UL94 antibodies bind to
NAG-2 on endothelial cells and induce apoptosis [60].
NAG-2 is also expressed on human fibroblasts and anti-
UL94 antibodies bind to fibroblasts that acquire a
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profibrotic phenotype [61]. Furthermore, hCMV-derived
UL70 protein shares homology with Topoisomerase I.
hCMV is also associated with increased risk of graft-ver-
sus-host disease (GVHD), a condition that develops after
bone marrow transplantation, shares clinical and serologi-
cal features with SSc and is considered a model for SSc
[62]. Murine CMV (mCMV) can invade endothelial cells
in mice and cause latency and intermittent shedding of the
virus. mCMV-infected irradiated interferon-c receptor
knock-out (IFNcR-/-) mice exhibit neointima formation
with myofibroblast proliferation in small vessels [63].
EBV is another candidate causative agent for SSc. EBV
is a lymphotropic virus infecting the vast majority of adult
population. EBV causes latency but is also reactivated into
lytic infection and, besides B cells, can infect the majority
of fibroblasts and endothelial cells in the skin of patients
with SSc. Furthermore, EBV activates fibroblasts towards
profibrotic phenotype through TLR, TGFb1 and endothelin
[64]. Parvovirus B19 may also participate in SSc patho-
genesis, since parvovirus B19 DNA was detected in the
bone marrow of SSc patients but not in controls [65].
Inflammasome, activated by dangerous stimuli and
through the action of caspase, induces the production of
inflammatory mediators, such as interleukin-1, and is
activated in SSc. Increased expression of NLRP3 and
AIM2 inflammasome proteins was detected in SSc skin
fibroblasts, while inhibition of caspace abrogated the
secretion of collagen, IL-1b and IL-18 [66]. It should be
mentioned that the AIM2 inflammasome is a sensor for
cytosolic bacterial and viral DNA [67].
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a multisystem dis-
ease affecting mostly women in reproductive years. It is
characterized by many autoantibodies [68], including
antinuclear antibodies, anti-dsDNA antibodies, anti-Sm
antibodies and anti-Ro antibodies. Both genetic and envi-
ronmental factors interplay for the development of the dis-
ease [69] as the concordance rate of SLE in monozygotic
twins (24 %) is higher than that in dizygotic twins (2 %)
[70]. EBV has long been suspected to play a pathogenic role
in SLE. EBV-IgA antibodies, which are thought to reflect
reactivation or re-infection with EBV, were associated with
SLE, particularly in African-Americans [71, 72]. Antibodies
to EBV nuclear antigen-1 (EBNA-1) and EBNA-2 cross-
react with SmD and 60 kD Ro, and mice or rabbits immu-
nized with EBNA-1 develop experimental lupus [73, 74]. It
should be mentioned that 44 % of patients with primary
acute EBV infection have serum antibodies against
extractable nuclear antigens (ENA) [75].
Retroviruses are also candidate agents in SLE [76].
Retroviruses are small viruses that use reverse transcription
for their replication. Human endogenous retroviruses
(HERV) are retroviruses thought to be trapped into the
human genome. These retroviruses can be activated by
many environmental factors, such as infections, ultraviolet
(UV) light, hormones, stress and drugs [76]. In EBV
latency infected B cells, there is transactivation of HERV-
K18 that codes for the env protein, a T cell superantigen. T
cell superantigens bind to Vb segment of T cell receptor
and activate a huge proportion of T cells. Another HERV,
HERV3, codes for an env protein expressed in placenta and
shares homology with the Ro antigen. For long it has been
known that mothers with anti-Ro antibodies have increased
risk for fetal heart block (congenital heart block, CHB) and
mothers of babies with CHB have anti-HERV3 antibodies
that bind to sections of fetal heart [77].
Epigenetic changes caused by infections may also be
another pathogenetic mechanism operating in SLE. Envi-
ronmental factors, such as infection, drugs, smoking and UV
light, cause oxidative stress and DNA demethylation of
certain genes, such as genes of CD4? T cells to become
autoreactive cells [78]. CD4? T cells treated with a DNA
methylation inhibitor (5-azacytidine, 5-azaC) overexpress
CD11a, perforin, CD40L (costimulatory molecule), CD70
(B cell costimulatory molecule), killer cell immunoglobulin-
like receptor (KIR, not normally expressed on T cells) and
stimulate autologous B cells. Similarly, CD4? T cells from
SLE patients overexpress CD11a, perforin (not normally
expressed in T cells), CD40L, CD70 and KIR [76, 78].
Sjo¨gren’s syndrome
Sjo¨gren’s syndrome (SS) is a chronic autoimmune disease,
more prevalent in women, affecting exocrine glads, mostly
salivary and lacrimal glands, but also extraglandular tissues
and organs. SS is characterized by relatively specific
autoantibodies, namely anti-Ro (SSA), anti-La (SSB), and
by ELS in exocrine glands. Hepatitis C virus (HCV), EBV
and human T cell leukemia virus (HTLV)1 have been put
forward as causative agents in SS. In a meta-analysis, SS has
been associated with HCV [79]. Active EBV infection
appears to cause expansion and differentiation of autoreac-
tive B cells in SS. Latent EBV and lytic EBV infection was
detected in ELS-containing SS salivary glands and plasma
cells with Ro52 immunoreactivity were frequently infected
by EBV. Furthermore, ELS-containing SS salivary glands
transplanted into SCID mice produced anti-Ro52 antibodies
and anti-EBV antibodies [41]. Commensal microbiota may
initiate autoimmunity in SS and SLE. For instance, peptides
from the von Willebrand factor type A from the oral
microbe Capnocytophaga ochracea activated HLADR3 (?),
Ro60-reactive T cells [80]. Environmental pollutants, such
as dioxin, through aryl hydrocarbon receptor, reactivates
(switches from latent to lytic infection) EBV in B cells and
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salivary epithelial cells [81]. HTLV1 is associated with SS
in endemic areas, such as Nagasaki in Japan [82, 83]. It
should be mentioned that HTLV1 preferentially transfects
CD4 ? T cells, but can also transfect human primary sali-
vary gland epithelial cells [82].
Vasculitis
Vasculitis is idiopathic inflammation of vessel wall. There
are various types of vasculitis classified according to vessel
size preferentially involved.
ANCA vasculitis
Vasculitis associated with anti-neutrophil cytoplasmic anti-
bodies (ANCA vasculitis) encompasses granulomatosis with
polyangiitis (GPA, formely Wegener’s granulomatosis),
eosinophilic granulomatosis with polyangiitis (EGPA, for-
mely Churg-Strauss syndrome) microscopic polyangiitis,
and pauci-immune glomerulonephritis (focal necrotizing
glomerulonephritis, FNGN). The characteristic features of
these vasculitides are the presence of ANCA in the sera of
patients and the absence of immune deposits in the glo-
meruli on immunofluorence in patients with glomeru-
lonephritis (pauci-immune GN). The mechanisms
responsible for the induction of these diseases are poorly
understood. Classical ANCA’s target is the antimicrobial
lysosomal enzyme either proteinase-3 or myeloperoxidase
[84]. A long standing clinical observation of increased fre-
quency of nasal carriage of S.aureus in patients with GPA
has linked ANCA vasculitis with infectious agents [85]. This
observation has led to antimicrobial treatment of GPA with
beneficial effects. Antibodies against complementary pro-
teinase-3 (cPR3) were found in GPA and cPR3 has
homology with S. aureus antigens [86]. A new and some-
what controversial ANCA subtype, namely anti-lysosomal
membrane protein-2 (LAMP-2), has been linked to ANCA-
associated vasculitis. Patients with FNGN have antibodies to
LAMP-2 epitope 41-49 that has 100 % homology with
FimH, an adhesion molecule present on Gram(-) bacteria
whereas immunization with FimH-induced anti-LAMP-2
antibodies and FNGN [87]. Thus, FNGN provides a direct
link for a molecular mimicry between bacteria and host
proteins. As found in RA, ANCA vasculitis is associated
with increased formation of NETs. NETs can provide
autoantigens to dendritic cells and activate B cells [88]. S.
aureus and ANCAs are strong inducers of NET formation
[89].
Other vasculitides
Other types of vasculitides are also associated with infec-
tious agents. Mixed cryoglobulinaemic vasculitis is
associated with HCV. In fact, 70–100 % of patients with
mixed cryoglobulinaemic vasculitis have evidence of HCV
infection, hence the term HCV-related mixed cryoglobu-
linaemia. HCV is a RNA virus and causes chronic infection
and hence persistent antigenic stimulus that leads to mon-
oclonal IgM rheumatoid factor production, immune com-
plex formation and complement activation [90].
Henoch-Schonlein purpura, a small vessel vasculitis,
primarily in children, has been associated with group A
streptococci, parvovirus B19 and others infectious agents.
Kawasaki disease, which affects medium-sized arteries, has
been associated with viral agents [91], and polyarteritis
nodosa is associated with hepatitis B virus [92].
Conclusion
Interaction between genes and environmental factors,
particularly infectious agents appear to be involved in
the development of autoimmune rheumatic diseases.
Thus far, cigarette smoking and infectious agents caus-
ing periodontitis are clearly two environmental agents
with the strongest evidence for interaction with genes
(HLA-DRB1*SE) in the pathogenesis of RA. The
definitive identification of infectious agents implicated in
other autoimmune rheumatic diseases requires further
investigations.
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